EP3452036A4 - USE OF TOPICAL FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF BLEED EPIDERMOLYSIS AND RELATED CONNECTIVE TISSUE DISORDERS - Google Patents

USE OF TOPICAL FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF BLEED EPIDERMOLYSIS AND RELATED CONNECTIVE TISSUE DISORDERS Download PDF

Info

Publication number: EP3452036A4
Authority: EP; European Patent Office
Prior art keywords: epidermolysis; cannabinoids; bleed; treatment; connective tissue
Prior art date: 2016-05-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP17792340.6A

Other languages

German (de)

French (fr)

Other versions

EP3452036A1 (en

Inventor

Sazzad HOSSAIN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Inmed Pharmaceuticals Inc

Original Assignee

Inmed Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-04

Filing date

2017-05-04

Publication date

2019-11-06

2017-05-04 Application filed by Inmed Pharmaceuticals Inc filed Critical Inmed Pharmaceuticals Inc

2019-03-13 Publication of EP3452036A1 publication Critical patent/EP3452036A1/en

2019-11-06 Publication of EP3452036A4 publication Critical patent/EP3452036A4/en

Status Pending legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Furan Compounds (AREA)
Pyrane Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

EP17792340.6A 2016-05-04 2017-05-04 USE OF TOPICAL FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF BLEED EPIDERMOLYSIS AND RELATED CONNECTIVE TISSUE DISORDERS Pending EP3452036A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662331633P	2016-05-04	2016-05-04
PCT/CA2017/050546 WO2017190249A1 (en)	2016-05-04	2017-05-04	Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders

Publications (2)

Publication Number	Publication Date
EP3452036A1 EP3452036A1 (en)	2019-03-13
EP3452036A4 true EP3452036A4 (en)	2019-11-06

Family

ID=60202544

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17792340.6A Pending EP3452036A4 (en)	2016-05-04	2017-05-04	USE OF TOPICAL FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF BLEED EPIDERMOLYSIS AND RELATED CONNECTIVE TISSUE DISORDERS

Country Status (9)

Country	Link
US (1)	US12042479B2 (en)
EP (1)	EP3452036A4 (en)
JP (2)	JP7054691B2 (en)
CN (1)	CN109689045A (en)
AU (1)	AU2017260706B2 (en)
CA (1)	CA3023049A1 (en)
IL (1)	IL262702B (en)
SG (1)	SG11201809688RA (en)
WO (1)	WO2017190249A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10640464B2 (en)	2011-01-03	2020-05-05	The William M. Yarbrough Foundation	Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
AU2017260706B2 (en)	2016-05-04	2023-05-11	Inmed Pharmaceuticals Inc.	Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
CA3052146A1 (en) *	2017-02-01	2018-08-09	Gbs Global Biopharma, Inc.	Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US11318179B2 (en) *	2017-06-20	2022-05-03	Jessica Kado	Topical formulation for binding to dermatological cannabinoid receptors
WO2019056123A1 (en) *	2017-09-22	2019-03-28	Inmed Pharmaceuticals Inc.	Topical formulations of cannabinoids and use thereof in the treatment of pain
WO2019191830A1 (en)	2018-04-04	2019-10-10	Vincenzo Maida	Topical cannabinoid formulations and instillates, kits, and methods for treating integumentary wounds, and uses thereof
WO2020051284A1 (en) *	2018-09-05	2020-03-12	Nemus Bioscience, Inc.	Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
EP3643303A1 (en) *	2018-10-22	2020-04-29	InnovativeHealth Group SL	Compounds for use in the treatment or prevention of fibrotic diseases; pharmaceutical, cosmetic compositions and uses thereof
WO2020142692A1 (en) *	2019-01-04	2020-07-09	Columbia Care Llc	Topical formulations having cannabinoid
CA3130763A1 (en)	2019-02-25	2020-09-03	Ginkgo Bioworks, Inc.	Biosynthesis of cannabinoids and cannabinoid precursors
WO2020234650A1 (en) *	2019-05-21	2020-11-26	Timeless Herbal Care (Canada) Ltd.	Pharmaceutical compositions comprising cbd and terpene compositions
CA3057647A1 (en) *	2019-10-03	2021-04-03	Vinsan Therapeutics Inc.	Topical formulations and instillates, kits, and methods for treating integumentary wounds, and uses thereof
US11160768B2 (en)	2019-10-22	2021-11-02	Edmund M. Dunn	Paraffin wax with CBD isolate
CN113116870A (en) *	2019-12-31	2021-07-16	四川大学	Application of cannabidiol in preparation of medicine for promoting oral mucosa healing
US20210236687A1 (en) *	2020-01-31	2021-08-05	Pac-Dent, Inc.	Cannabinoid-based oral hemostatic compositions
MX2022009507A (en) *	2020-02-06	2022-11-09	London Pharmaceuticals And Res Corporation	SULFATE ESTERS OF CANNABINOIDS, THEIR SALTS AND USES THEREOF.
EP4430023A1 (en) *	2021-11-10	2024-09-18	London Pharmaceuticals and Research Corporation	New cannabinoid-gabapentinoid conjugates and uses thereof
KR20250109184A (en) *	2022-09-19	2025-07-16	브라이트씨드, 인크.	Compositions and methods for improving intestinal permeability
WO2024108201A2 (en) *	2022-11-18	2024-05-23	Bazelet Health Systems, Inc.	Cannabigerolic acid (cbga) and cannabigerol (cbg) derived products and methods of use
CN116602268B (en) *	2023-02-24	2024-01-05	中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所)	Application of gene knockout mutant zebrafish in preparing animal models of pigmentation reduction

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010013240A1 (en) *	2008-07-31	2010-02-04	Dekel Pharmaceuticals Ltd.	Compositions and methods for treating inflammatory disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19706903A1 (en)	1997-02-21	1998-08-27	Bayer Ag	Use of known agonists of the central cannabinoid receptor CB 1
EP1645270B1 (en)	1998-05-29	2010-04-28	Neurosciences Research Foundation Inc.	Control of pain with ANANDAMIDE
JP2002520282A (en)	1998-07-09	2002-07-09	フランシスエイ．ナーデラ，	Methods and compositions for the treatment of chronic lymphocytic leukemia
US6566560B2 (en)	1999-03-22	2003-05-20	Immugen Pharmaceuticals, Inc.	Resorcinolic compounds
US6921722B2 (en)	2000-05-30	2005-07-26	Ebara Corporation	Coating, modification and etching of substrate surface with particle beam irradiation of the same
US8449908B2 (en)	2000-12-22	2013-05-28	Alltranz, Llc	Transdermal delivery of cannabidiol
US7109216B2 (en)	2001-09-21	2006-09-19	Solvay Pharmaceuticals B.V.	1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
US6825209B2 (en)	2002-04-15	2004-11-30	Research Triangle Institute	Compounds having unique CB1 receptor binding selectivity and methods for their production and use
CA2524251A1 (en)	2003-05-01	2004-11-11	Vernalis Research Limited	Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders
JP2007507523A (en)	2003-10-02	2007-03-29	セフアロン・インコーポレーテツド	Substituted indole derivatives
FR2864958B1 (en)	2004-01-12	2006-02-24	Sanofi Synthelabo	N - [(1,5-DIPHENYL-1H-PYRAZOL-3-YL) METHYL] SULFONAMIDE DERIVATIVE, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
TWI330635B (en)	2004-03-05	2010-09-21	Organon Nv	(indol-3-yl)-heterocycle derivatives
EP1588697A1 (en)	2004-04-16	2005-10-26	Kurt H. Prof. Dr. Bauer	Emulsion gel for topical application of pharmaceuticals
GB2414933B (en)	2004-06-08	2009-07-15	Gw Pharma Ltd	Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
WO2006111424A1 (en) *	2005-04-22	2006-10-26	Life & Brain Gmbh	Methods for identifying modulators of cb1 and cb2 cannabinoid receptors and their use in wound healing
GB2432312A (en)	2005-11-01	2007-05-23	Gw Pharma Ltd	Pharmaceutical compositions for the treatment of pain
GB2439393B (en)	2006-06-23	2011-05-11	Gw Pharma Ltd	Cannabinoids for use in the treatment of neuropathic pain
BRPI0714199A2 (en)	2006-07-04	2012-12-25	Janssen Pharmaceutica Nv	benzimidazole cannabinoid agonists carrying a substituted heterocyclic group
US9394267B2 (en)	2007-07-13	2016-07-19	The Cleveland Clinic Foundation	Heterocyclic modulators of cannabinoid receptors
EP2424525A1 (en)	2009-04-28	2012-03-07	AllTranz Inc.	Formulations of cannabidiol and methods of using the same
WO2010126501A1 (en)	2009-04-29	2010-11-04	University Of Kentucky Research Foundation	Cannabinoid-containing compositions and methods for their use
SG10201404925TA (en)	2009-08-28	2014-10-30	Arena Pharm Inc	Cannabinoid receptor modulators
GB2524689B (en)	2011-05-20	2016-01-27	Gw Pharma Ltd	Cannabinoids for use in the treatment of neuropathic pain
US9133128B2 (en)	2011-06-17	2015-09-15	Research Triangle Institute	Pyrazole derivatives as cannabinoid receptor 1 antagonists
CA2866787C (en)	2011-09-29	2021-05-18	Thc Pharm Gmbh The Health Concept	Cannabinoid carboxylic acids, salts of cannabinoid carboxylic acids, and the production and uses of same
AU2014347807A1 (en)	2013-10-31	2016-05-26	Full Spectrum Laboratories, Ltd.	Terpene and cannabinoid formulations
US20160022627A2 (en)	2014-04-18	2016-01-28	Mary's Medicinals LLC	Transdermal cannabinoid patch
US10028904B2 (en)	2014-12-04	2018-07-24	Wisconsin Alumni Research Foundation	Transdermal cannabinoid formulations
US9375417B2 (en)	2014-12-04	2016-06-28	Mary's Medicinals LLC	Transdermal cannabinoid formulations
GB2542797A (en) *	2015-09-29	2017-04-05	Gw Pharma Ltd	Use of cannabinoids in the treatment of inflammatory skin diseases
PL3429580T3 (en)	2016-03-16	2025-09-22	Buzzelet Development And Technologies Ltd	CANNABINOID COMPOSITION ENRICHED WITH TERPENES
AU2017260706B2 (en)	2016-05-04	2023-05-11	Inmed Pharmaceuticals Inc.	Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders

2017
- 2017-05-04 AU AU2017260706A patent/AU2017260706B2/en active Active
- 2017-05-04 US US16/098,324 patent/US12042479B2/en active Active
- 2017-05-04 WO PCT/CA2017/050546 patent/WO2017190249A1/en not_active Ceased
- 2017-05-04 JP JP2019510730A patent/JP7054691B2/en active Active
- 2017-05-04 CN CN201780041674.8A patent/CN109689045A/en active Pending
- 2017-05-04 EP EP17792340.6A patent/EP3452036A4/en active Pending
- 2017-05-04 CA CA3023049A patent/CA3023049A1/en active Pending
- 2017-05-04 SG SG11201809688RA patent/SG11201809688RA/en unknown
2018
- 2018-10-31 IL IL262702A patent/IL262702B/en unknown
2022
- 2022-04-04 JP JP2022062473A patent/JP7342183B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010013240A1 (en) *	2008-07-31	2010-02-04	Dekel Pharmaceuticals Ltd.	Compositions and methods for treating inflammatory disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "CBD For Skin Conditions - Cannabidiol Salve, Balms, Creams", BUYCBDOILONLINE, 13 June 2014 (2014-06-13), pages 1 - 8, XP055550284, Retrieved from the Internet <URL:http://www.buycbdoilonline.info/2014/06/cbd-skin-conditions> [retrieved on 20190131] *
ANONYMOUS: "News Releases-InMed Pharmaceuticals", 4 November 2015 (2015-11-04), XP055784310, Retrieved from the Internet <URL:https://investors.inmedpharma.com/news-releases?item=74> [retrieved on 20210310] *
JOUNI UITTO ET AL: "Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 136, no. 2, 1 February 2016 (2016-02-01), NL, pages 352 - 358, XP055352164, ISSN: 0022-202X, DOI: 10.1016/j.jid.2015.10.050 *
MARIANGELA PUCCI ET AL: "Epigenetic control of skin differentiation genes by phytocannabinoids : Epigenesis of skin genes by phytocannabinoids", BRITISH JOURNAL OF PHARMACOLOGY, vol. 170, no. 3, 17 September 2013 (2013-09-17), UK, pages 581 - 591, XP055508939, ISSN: 0007-1188, DOI: 10.1111/bph.12309 *
See also references of WO2017190249A1 *

Also Published As

Publication number	Publication date
CA3023049A1 (en)	2017-11-09
IL262702A (en)	2018-12-31
JP2019518075A (en)	2019-06-27
EP3452036A1 (en)	2019-03-13
SG11201809688RA (en)	2018-11-29
AU2017260706B2 (en)	2023-05-11
JP7342183B2 (en)	2023-09-11
CN109689045A (en)	2019-04-26
JP7054691B2 (en)	2022-04-14
AU2017260706A1 (en)	2018-11-22
IL262702B (en)	2022-06-01
WO2017190249A1 (en)	2017-11-09
JP2022084953A (en)	2022-06-07
US20190142788A1 (en)	2019-05-16
US12042479B2 (en)	2024-07-23

Publication	Publication Date	Title
EP3452036A4 (en)	2019-11-06	USE OF TOPICAL FORMULATIONS OF CANNABINOIDS FOR THE TREATMENT OF BLEED EPIDERMOLYSIS AND RELATED CONNECTIVE TISSUE DISORDERS
EP3448398A4 (en)	2019-12-18	COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
MA45481A (en)	2018-04-18	USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
EP3328492A4 (en)	2019-06-19	PHOTOTHERAPY DEVICES FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS OF SCALP
MA46052A (en)	2021-03-17	HORMONAL RECEPTOR MODULATORS FOR TREATMENT OF METABOLIC CONDITIONS AND DISORDERS
EP3463315A4 (en)	2020-01-15	COMPOSITIONS AND METHODS OF USE OF NINTEDANIB FOR THE TREATMENT OF ABNORMAL NEOVASCULARIZED EYE DISEASE
SI3377637T1 (en)	2020-08-31	Compositions for use in procedures for the treatment of wounds, disorders and skin diseases
MA45089A (en)	2019-04-10	USE OF 2-SUBSTITUTE INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES
EP3368560A4 (en)	2019-03-27	FACTOR VIII-REDUCED FACTOR VARIANTS, COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF HEMOSTATIC DISORDERS
EP3704108A4 (en)	2021-08-25	COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF BLOOD DISORDERS
EP3829569A4 (en)	2022-04-27	FORMULATIONS OF SPINOSYNE FOR THE TREATMENT OF EYE AND FACIAL DISEASES CAUSED BY DEMODEX
EP3512517A4 (en)	2020-05-06	USE OF PRIDOPIDINE FOR THE TREATMENT OF ANXIETY AND DEPRESSION
EP3180022A4 (en)	2019-02-20	IMPROVED EXPRESSION CASSETTE FOR CONDITIONING AND EXPRESSION OF FACTOR VIII VARIANTS FOR THE TREATMENT OF HEMOSTASE DISORDERS
EP2983619A4 (en)	2016-10-05	SURGICAL ORIENTATION AND PLANNING SOFTWARE FOR THE TREATMENT OF ASTIGMATISM
EP3368088C0 (en)	2023-06-07	COMPOSITIONS AND METHODS FOR THE TREATMENT OF PEROXISOMAL DISORDERS AND LEUCODYSTROPHIES
MA44737A (en)	2021-04-07	COMPOSITIONS FOR THE TREATMENT OF DISORDERS RELATED TO HYPERKERATOSIS
EP3639833A4 (en)	2021-03-10	AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO FAT AND / OR INFLAMMATION
EP3328864A4 (en)	2019-01-09	COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
MA51056A (en)	2020-10-14	COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
IL268720A (en)	2019-10-31	Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
EP3458079A4 (en)	2020-03-04	COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACNE
EP3363450A4 (en)	2019-04-10	CHINESE TRADITIONAL MEDICINE COMPOSITION FOR THE TREATMENT OF PSORIASIS
EP3352749A4 (en)	2019-09-04	COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS
MA49794A (en)	2020-06-03	COMPOSITION USED IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF DISORDERS OF THE CARDIOVASCULAR SYSTEM
MA49140A (en)	2020-03-25	MERGED HETEROAROMATIC-ANILINE COMPOUNDS FOR THE TREATMENT OF DERMAL DISORDERS

Legal Events

Date	Code	Title	Description
2017-11-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-02-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-02-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-03-13	17P	Request for examination filed	Effective date: 20181114
2019-03-13	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-03-13	AX	Request for extension of the european patent	Extension state: BA ME
2019-08-07	DAV	Request for validation of the european patent (deleted)
2019-08-07	DAX	Request for extension of the european patent (deleted)
2019-11-06	A4	Supplementary search report drawn up and despatched	Effective date: 20191009
2019-11-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/343 20060101ALI20191002BHEP Ipc: A61K 31/352 20060101AFI20191002BHEP Ipc: A61K 31/4172 20060101ALI20191002BHEP Ipc: A61K 31/473 20060101ALI20191002BHEP Ipc: A61P 17/00 20060101ALI20191002BHEP Ipc: A61K 31/415 20060101ALI20191002BHEP Ipc: A61K 31/397 20060101ALI20191002BHEP Ipc: A61K 31/05 20060101ALI20191002BHEP Ipc: A61K 31/404 20060101ALI20191002BHEP Ipc: A61K 31/4162 20060101ALI20191002BHEP Ipc: A61K 31/122 20060101ALI20191002BHEP Ipc: A61K 31/5383 20060101ALI20191002BHEP
2020-03-18	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: INMED PHARMACEUTICALS INC.
2021-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-04-21	17Q	First examination report despatched	Effective date: 20210318